Evidence that p-cresol and IL-6 are adsorbed by the HFR cartridge: Towards a new strategy to decrease systemic inflammation in dialyzed patients?

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Riccio, Eleonora ^a   Cataldi, Mauro ^a   Minco, Maristella ^a   Argentino, Gennaro ^a   Russo, Roberta ^a   Brancaccio, Stefania ^a   Memoli, Andrea ^a   Grumetto, Lucia ^a   Postiglione, Loredana ^a   Guida, Bruna ^a   Memoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; PARA CRESOL; 4-CRESOL; CRESOL; HEMODIALYSIS FLUID; SERUM ALBUMIN;

ADSORPTION; ADULT; ARTICLE; CARTRIDGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS EQUIPMENT AND SUPPLIES; FEMALE; HEMO FILTRATE REINFUSION; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; AGED; BLOOD; CHEMISTRY; COMPLICATION; DEVICES; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES;

ADSORPTION; AGED; CRESOLS; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS SOLUTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; SERUM ALBUMIN;

EID: 84899679204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095811     Document Type: Article

References (50)

1. Shiffer EL, Lipman ML, Mann FE (2007) Chronic kidney disease: effect on the cardiovascular system. Circulation 116: 85-97. (Pubitemid 47016250)
2. Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9: S16-S23.
3. Sarnak M, Coronado B, Greene T (2002) Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335. (Pubitemid 34477469)
4. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, et al. (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505-521.
5. Kaysen GA (2001) The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12: 1549-1557.
6. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E (2005) Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68: 429-436. (Pubitemid 43323098)
7. Levin A (2002) Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int 61 (Suppl. 80): S35-S38.
8. Cummings JH (1983) Fermentation in the human large intestine: evidence and implications for health. Lancet 1: 1206-1209.
9. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K (2009) Uremic toxins originating from colonic microbial metabolism. Kidney Int 76 (Suppl 114): S12-S19.
10. Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, et al. (2011) Warning: The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 26: 1464-1467.
11. Meijers BKI, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, et al. (2008) Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1173-1180.
12. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y (2006) Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69:1081-1087. (Pubitemid 43372184)
13. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, et al. (2004) P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92:140-150. (Pubitemid 39010877)
14. Ying Y, Yang K, Liu Y, Chen QJ, Shen WF, et al. (2011) A uremic solute, P-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Circ J 75: 2252-2259.
15. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, et al. (2009) The uremic retention solute p-cresylsulfate and markers of endothelial damage. Am J Kidney Dis 54: 891-901.
16. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, et al. (2007) P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant; 22 592-596. (Pubitemid 46189906)
17. Stenvinkel P, Heinburger O, Paultre F, Diczfalusy U, Wang T, et al. (1999) Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911. (Pubitemid 29197978)
18. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis. Kidney Int 55: 648-658 (Pubitemid 29082891)
19. Serur D, Stenzel KH, Rubin AL. (1998) Interleukin 6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32: 107-114. (Pubitemid 28311878)
20. Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, et al. (2008) Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies: Results from the RISCAVID study. Nephrol Dial Transplant 23: 2337-2343. (Pubitemid 351957592)
21. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476. (Pubitemid 30124077)
22. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, et al. (2005) Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 45: 324-333. (Pubitemid 40431059)
23. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, et al. (2010) Plasma Interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney diasease. Kidney Int 77: 550-556.
24. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, et al. (2005) IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67: 1216-1233. (Pubitemid 40463099)
25. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, et al. (2009) Protein-Bound Toxins-Update in 2009. Seminars in Dialysis 22: 334-339.
26. Martinez AW, Recht NS, Hostetter TH, Meyer TW (2005) Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 16: 3430-3436. (Pubitemid 46187553)
27. Tarakçioǧlu M, Erbaǧci AB, Usalan C, Deveci R, Kocabaş R (2003) Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm 12: 15-19.
28. Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, et al. (2009) p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 4: 1932-1938.
29. Vanhoder R, Glorieux G, Lameire N, European Uremic Toxin Work Group (2003) Uraemic toxins and cardiovascular disease.Nephrol Dial Transplant 18: 463-466. (Pubitemid 36312938)
30. Memoli B, Grandaliano G, Soccio M, Postiglione L, Guida B, et al. (2005) In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD. J Am Soc Nephrol 16:1099-1107. (Pubitemid 41710321)
31. Meyer TW, Peattie JW, Miller JD, Dinh DC, Recht NS, et al. (2007) Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysis. J Am Soc Nephrol 18: 868-874. (Pubitemid 46434503)
32. Meijers BK, Weber V, Bammens B, Dehaen W, Verbeke K, et al. (2007) Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 32: 214-219. (Pubitemid 351326755)
33. Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, et al. (2010) Protein-bound uraemic toxin removal in haemodialysis and post-diluition haemodiafiltration. Nephrol Dial Transplant 25: 212-218.
34. Ghezzi PM, Gervasio R, Tessore V, Sartoris AM, Botella J. (1992) Hemodiafiltration without replacement fluid: an experimental study. ASAIO Journal 38: 61-65.
35. de Francisco ALM, Ghezzi PM, Brendolan A, Fiorini F, La Greca G, et al. (2000) Hemodiafiltration with on-line regeneration of the ultrafiltrate. Kidney Int 58: S66-S71.
36. Memoli B, Bisesti V, Saravo MT, Esposito P, D'Arcangelo R, et al. (2003) Cytokine production in standard hemodialysis with a new polyethersulfone membrane: a cross-over study. Contrib Nephrol 138:80-87.
37. Wratten ML, Sereni L, Lupotti M, Ghezzi PM, Atti M, et al. (2004) Optimization of a HFR sorbent cartridge for high molecular weight uremic toxins. G Ital Nefrol 21: S67-S70.
38. De Nitti C, Giordano R, Gervasio R, Castellano G, Podio V, et al. (2001) Choosing new sorbents for endogenous ultrapure infusion fluid: performances, safety and flow distribution. Int J Artif Organs 24: 765-776. (Pubitemid 34168268)
39. Tetta C, Ghezzi PM, De Nitti C, Fiorenzi A, Cianciavicchia D, et al. (2002) New options for on-line hemodiafiltration. Contrib Nephrol 137: 212-220.
40. Guida B, Cataldi M, Riccio E, Grumetto L, Pota A, et al. (2013) Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. PLoS One 8: e73558.
41. Calaf R, Cerini C, Génovésio C, Verhaeghe P, Jourde-Chiche N, et al. (2011) Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. J Chromatogr B Analyt Technol Biomed Life Sci 879:2281-2286.
42. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, et al. (2000) Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15: 50-57. (Pubitemid 30037930)
43. Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, et al. (2003) The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech14: 33-43.
44. Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, et al. (2000) Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int, 58: 417-424. (Pubitemid 30429890)
45. Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, et al. (2011) Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant 26: 2624-2630.
46. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, et al. (2009) Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 24: 562-570.
47. Memoli B, Salerno S, Procino A, Postiglione L, Morelli S, et al. (2010) A translational approach to micro-inflammation in end-stage renal disease: molecular effects of low levels of interleukin-6. Clin Sci 119: 163-174.
48. Sander A, Armbruster W, Sander B, Daul AE, Lange R, et al. (1997) Hemofiltration increases IL-6 clearance in early systemic response syndrome but does not alter IL-6 and TNFα plasma concentrations. Intensive Care Med 23: 878-884. (Pubitemid 27417692)
49. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, et al. (1997) Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome. Renal Failure 19: 443-454. (Pubitemid 27203129)
50. Calò LA, Naso A, Carraro G, Wratten ML, Pagnin E, et al. (2007) Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 22: 1413-1419.